Patent ID: 11932854
Assignee: SIRNA THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 2:
3. The composition according to claim 1, wherein:
(a) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in NX4 positions are 2′-O-methyl nucleotides;
(b) 5, 6, 7, 8, 9, 10 or more purine nucleotides in NX4 positions are 2′-deoxy-2′-fluoro nucleotides;
(c) 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides in NX3 positions are 2′-O-methyl nucleotides;
(d) 5, 6, 7, 8, 9, 10 or more purine nucleotides in NX3 positions are 2′-deoxy-2′-fluoro nucleotides; and
(e) [N] position nucleotide(s) are any combination of ribonucleotides, deoxyribonucleotides, 2′-O-alkyl nucleotides, or 2′-halo nucleotides.